- Home
- EDBL vs MBIO Comparison
EDBL vs MBIO Comparison
Compare EDBL & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDBL | MBIO |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | United States |
| Employees | 99 | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8M | 7.0M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | EDBL | MBIO |
|---|---|---|
| Price | $2.94 | $0.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 75.3K | 44.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $29.56 | N/A |
| Revenue Next Year | $20.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.44 | $0.53 |
| 52 Week High | $7.54 | $7.00 |
Technical Indicators
Market Signals| Indicator | EDBL | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 54.05 | 40.78 |
| Support Level | $2.49 | $0.53 |
| Resistance Level | $4.15 | $1.10 |
| Average True Range (ATR) | 0.27 | 0.07 |
| MACD | -0.14 | -0.00 |
| Stochastic Oscillator | 35.40 | 14.20 |
Price Performance
Historical ComparisonAbout EDBL Edible Garden AG Incorporated
Edible Garden AG Inc is a next-generation controlled environment agriculture farming company. It uses traditional agricultural growing techniques together with technology to grow fresh, organic food, sustainably and safely while improving traceability. The company uses the controlled environment of traditional greenhouse structures, such as glass greenhouses together with hydroponic and vertical greenhouses to sustainably grow organic herbs and lettuces.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.